# Velano Vascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/velano-vascular

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.velanovascular.com
- Total disclosed funding: $26M
- Latest round: Series B (Jan 12, 2017)
- Investors on record: 8

## About

Velano Vascular, Inc. is a healthcare technology company focused on enhancing patient care through innovative vascular access solutions. Their primary goal is to improve the experience of blood draws for patients and medical professionals alike.Founded in 2012, Velano Vascular, Inc. is based in San Francisco, US. The company specializes in developing solutions that simplify and enhance vascular access for blood sampling, positioning itself effectively within the healthcare industry. In July 2021, Becton, Dickinson & Company Platforms acquired Velano Vascular, Inc. from several investors including Kapor Capital and First Round Capital. The company has successfully raised USD 15.00 mn through its latest round of funding, which is also the total amount raised. They have completed a total of 9 deals, with the most recent deal occurring on July 20, 2021.Velano Vascular's core products are designed to streamline the blood draw process, minimizing discomfort for patients and improving efficiency for healthcare providers. Their flagship product addresses critical challenges faced in vascular access, enhancing the overall user experience. The company serves a diverse clientele, from small healthcare facilities to large hospitals across North America, Europe, and parts of Asia, ensuring accessibility and support for their innovative solutions.Velano Vascular operates on a revenue model that combines direct sales and subscription services, allowing flexibility in client engagement. The company typically establishes agreements for ongoing access to its innovative solutions, with pricing plans tailored for various organizational needs. Additionally, partnerships with healthcare providers assist in distributing their products effectively while maintaining direct client relationships. This framework supports steady revenue generation through a combination of product sales and consulting services, nurturing long-term client satisfaction.Looking ahead, Velano Vascular plans to leverage the recent funding to expand its product offerings and enhance their market presence. While specific upcoming product launches have not been disclosed, the company aims to target new geographic regions for expansion, potentially focusing on European and Asian markets in the coming years. The acquisition by Becton, Dickinson & Company Platforms in July 2021 is expected to facilitate access to larger distribution networks, further supporting these growth initiatives.

## Funding rounds

- Series B, Jan 12, 2017, $17M — Safeguard Scientifics, First Round Capital, Kapor Capital, Sutter Health, White Owl Capital
- Series A, Feb 8, 2016, $3.5M — Safeguard Scientifics, First Round Capital, Kapor Capital, White Owl Capital, The Children's Hospital of Philadelphia, DW Partners, Griffin Hospital
- Series A, Feb 5, 2015, $5M — Safeguard Scientifics, First Round Capital, Kapor Capital, White Owl Capital, The Children's Hospital of Philadelphia, Griffin Hospital
- Seed, Nov 12, 2014, $0.4M — First Round Capital

## Investors

- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Seed, Series A, Series B
- Safeguard Scientifics (https://capitalatlas.ai/funds/safeguard-scientifics) — Series A, Series B
- Kapor Capital (https://capitalatlas.ai/funds/kapor-capital) — Series A, Series B
- White Owl Capital — Series A, Series B
- The Children's Hospital of Philadelphia — Series A
- Griffin Hospital — Series A
- DW Partners — Series A
- Sutter Health — Series B